Merck KGaA and Hoffmann-La Roche are seeking FDA approval for combination treatments and expanding pneumococcal vaccine labels.

The entities involved

• Merck KGaA →

  German multinational science and technology company

  • MSD, which operates as Merck & Co. in the US and Canada, has appointed Vidhya as Associate Vice President.Mon 12:02
  • Merck KGaA filed required 13F reports with the Securities and Exchange Commission regarding institutional holdings on June 15, 2026.Mon 02:05
• Hoffmann-La Roche →

  Swiss healthcare company

  • Natera's Signatera test is undergoing a Phase III trial across US sites, sponsored by NRG Oncology, while facing patent litigation.Sun 02:44
  • Hoffmann-La Roche opened a new R&D center in Boston.Sat 11:08

Related events

• The FDA has delayed potential approval of a cancer treatment that utilizes Exelixis in combination with Roche's Tecentriq.Sep 11
• Drug approvals are pending from the FDA, while GSK seeks to challenge competitor lung cancer treatments, adding near-approval therapies to its portfolio.Jun 11
• The FDA granted use authorizations for the OraSure kit used in conjunction with Hoffmann-La Roche molecular testing.Sep 6
• The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.Sep 14